All News

Why is lupus nephritis mortality trending up in the US, in contrast to overall SLE mortality? Race matters Urban location can make things worse I'm outside looking in but hope it's not too bold to say disparities affect whether you live or die from LN #ACR21 ABST0454 @RheumNow https://t.co/wmB9l9fFTT
David Liew drdavidliew ( View Tweet)
Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA. 90% LVV, 10% cranial GCA. Abstr#0466 #ACR21 @RheumNow https://t.co/PDCynMAigi
Richard Conway RichardPAConway ( View Tweet)
#ACR21 #ACRbest @RheumNow Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four European axSpA patients have difficulty in finding a job.

swethaann23 swethaann23 ( View Tweet)

Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categories (96%.) Quick ASDAS-qCRP can be used in real time to make clinical decisions. Abs 0374 #ACR21 #RheumNow @RheumNow https://t.co/opOyedQUaZ https://t.co/aeUEsW9HsX

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Do RA autoantibodies incr the risk of MACE? In study of ~2000 pts, ⬆️ concentrations of RA-related autoantibodies assoc. w/ MACE and/or CVD-mortality. Autoantibodies may therefore directly contribute to excess CVD risk in RA... Abs#0269 #ACR21 @RheumNow https://t.co/ju3YCRonJt https://t.co/UcOMsYxVMP

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Which pt has more MIs post elective surgery? #ACR21 @RheumNow abst#0128

Janet Pope Janetbirdope ( View Tweet)

Finally a way to improve Fatigue in RMDs? PLUS it is non pharmaceutical and remote⚡️! Cognitive Behavioural approaches and Personalised Exercise Interventions: ⬇️ Fatigue Severity and Impact ⬆️ Sleep at 1yr in a multiarm RCT. #OP0462 @RheumNow #ACR2021 https://t.co/5buGCYb5Ut https://t.co/4Wz2VmcL3x

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Winning Image Competition: Rheum Dz in Patients of Color: Dermatomyositis #ACR21 @rheumnow https://t.co/OFRDDgQqas
TheDaoIndex KDAO2011 ( View Tweet)
Erosive polyarticular chronic tophaceous gout Regional Winner of East Asia and Pacific Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/1wrNAhjsw6
TheDaoIndex KDAO2011 ( View Tweet)
SLE patients with +aPL was associated with: ➡️Nephritis ➡️Discoid rash ➡️Serositis ➡️Neurologic disorder Consider aPL and LAC status in patients w/these manifestations and whether anticoagulation/antiplatelets may be needed #ACR21 Abst#0077 @RheumNow

Pedro Castillo _Castillo_Pedro ( View Tweet)

Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation Regional Winner of Europe & Central Asia Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/vxayxgINa8
TheDaoIndex KDAO2011 ( View Tweet)
Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans Regional Winner of Latin America and Caribbean Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/4oAXIClwsm
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

Links:

Eric Dein ericdeinmd ( View Tweet)
#SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matched controls. Esp driven by comorbidities. Should we add ASA post op in SLE pts with CV risks? #ACR21 #abst0128 @RheumNow https://t.co/COdbDxFgBQ
Janet Pope Janetbirdope ( View Tweet)

Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
TheDaoIndex KDAO2011 ( View Tweet)
Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 Abst#0454 Lupus nephritis mortality from 1999-2019 ⭐️-27% age-standardized mortality rate in LN death, though increased trend in last 5 yrs! ▶️ Afr-American 38% of deaths, though 12% of population (RR ~4.5), ⬆️mortality with urbanization https://t.co/fjeGXtItvD @RheumNow https://t.co/cE3t6lq8zi

Links:

Eric Dein ericdeinmd ( View Tweet)
×